Fort Dodge Reintroduces ProHeart 6 to U.S. Market
By: Fort Dodge Press release
Read By: Pet Lovers
About Heartworm Disease
Heartworm disease is a potentially deadly disease affecting the U.S. canine population. Spread by mosquitoes, it can cause serious damage to the heart and pulmonary arteries eventually leading to heart failure. In severe cases, heartworm disease can damage other organs such as the liver and kidneys. Clinical signs of heartworm disease may not be recognized in the early stages, as heartworms may accumulate gradually over a period of months and sometimes years. Heavily infected animals may show clinical signs including mild, persistent cough, reluctance to move or exercise, tiredness after only moderate exercise, reduced appetite and weight loss. Prevention of heartworm disease is the best alternative, as treatment can result in death, severe allergic reactions or pulmonary embolism.
The statements in this press release that are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; economic conditions including interest and currency exchange rate fluctuations; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2007, which was filed with the Securities and Exchange Commission on Februa ry 29, 2008. The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
ProHeart® 6 is generally well tolerated. Do not use in sick, debilitated or underweight animals, animals with a history of weight loss, or within one month of vaccination. Use with caution in dogs with pre-existing allergic disease. A small percentage of dogs showed mild, transient swelling or itching at the injection site. While rare, allergic, digestive, hematological, or neurological reactions may occur. In addition, death has been reported. ProHeart 6 is available only through a restricted distribution program. Only veterinarians enrolled in this program can receive and administer ProHeart 6. In addition, ProHeart 6 must only be administered to clients whose owners have been advised of the risks of ProHeart 6 and sign an Owner Consent Form. To obtain additional information including a copy of the product labeling, visit the website at http://ac.acidirect.net/c.asp?709669&1744501031ab3d03&4 or call 1-800-533-8536.